Andere Sprachen Zai Lab Limited

Aktien

A2DX1V

US98887Q1040

ZLAB

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 31.05.2024			% 5 Tage	% 1. Jan.
17,78 ^USD	-2,25 %		-0,78 %	-34,94 %

24.05.	Asiatische Aktien, die in den USA als American Depositary Receipts gehandelt werden, tendieren im Freitagshandel höher und beenden die Woche niedriger	MT
22.05.	Zai Lab verabreicht ersten Patienten in einer klinischen Phase-2-Studie zur Behandlung von Plaque-Psoriasis; Aktien steigen an	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Asian Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading, End Week Lower	24.05.
Zai Lab Doses First Patient in a Phase 2 Clinical Trial of Plaque Psoriasis Treatment; Shares Rise	22.05.
Zai Lab Limited Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque Psoriasis	22.05.
Chinese Regulator Approves Zai Lab’s New Drug Application for Bacterial Pneumonia Drug	20.05.
Zai Lab, Innoviva Subsidiary Receive China Approval for Hospital Infection Treatment	20.05.
Zai Lab and Innoviva Specialty Therapeutics Announces NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China	20.05.
Asian Equities Traded in the US as American Depositary Receipts Ease in Thursday Trading	16.05.
Zai Lab's Supplemental Application for Autoimmune Disease Treatment Accepted by China Regulator	14.05.
Zai Lab Announces Acceptance of Supplemental Biologics License Application with Priority Review for Efgartigimod Alfa Injection (Subcutaneous Injection) in Chronic Inflammatory Demyelinating Polyneuropathy in China	14.05.
Asian Equities Traded in the US as American Depositary Receipts Begin Week Higher	13.05.
Zai Lab Says China Approves New Drug Application for Lung Cancer Treatment Augtyro	13.05.
Zai Lab Limited Announces Approval of AUGTYRO (repotrectinib) for Patients with ROS1-positive NSCLC by China?s NMPA	13.05.
Zai Lab's Shares Rise After Q1 Beat	09.05.
Asian Equities Traded in the US as American Depositary Receipts Trend Lower Thursday	09.05.
Top Premarket Gainers	09.05.
Transcript : Zai Lab Limited, Q1 2024 Earnings Call, May 09, 2024	09.05.
Zai Lab Q1 Loss Widens Despite Higher Revenue	09.05.
Zai Lab Limited Reports Earnings Results for the First Quarter Ended March 31, 2024	08.05.
Tech Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Slightly Higher in Monday Trading	06.05.
Asian Equities Traded in the US as American Depositary Receipts Rise Sharply in Friday Trading, End Week Over 2% Higher	03.05.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Zai Lab Limited

Aktien

A2DX1V

US98887Q1040

ZLAB

Andere Sprachen

Filter